T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient Mice Using Anti-Natural Killer Cell Antibody and Photochemically Treated Sensitized Donor T Cells  by Xiao, Tony Z. et al.
From the
of Pe
Child
of Cal
fornia
Financial d
Correspon
UCSF
Franc
Received J
 2012 Am
1083-8791
doi:10.101
200T Cell and B Cell Immunity can be Reconstituted
with Mismatched Hematopoietic Stem Cell
Transplantation Without Alkylator Therapy
in Artemis-Deficient Mice Using Anti-Natural Killer
Cell Antibody and Photochemically Treated
Sensitized Donor T Cells
Tony Z. Xiao,1 Kanal Singh,1 Elizabeth Dunn,1 Rageshree Ramachandran,2Morton J. Cowan12 2 1Children with Artemis-deficient T B NK severe combined immunodeficiency are at high risk for graft re-
jection from natural killer (NK) cells and toxicity from increased sensitivity to the alkylating agents used in
mismatched hematopoietic stem cell transplantation (HSCT). We evaluated the use of a nonalkylating agent
regimen before HSCT in Artemis-deficient (mArt2/2) C57Bl/6 (B6) mice to open marrow niches and achieve
long-term multilineage engraftment with full T cell and B cell immune reconstitution. We found that partial
depletion of both recipient NK cells using anti-NK1.1 monoclonal antibody and donor T cells sensitized to
recipient splenocytes was necessary. BALB/c-sensitized T cells (STCs) were photochemically treated (PCT)
with psoralen and UVA light to inhibit proliferation, reduce the risk of graft-versus-host disease (GVHD), and
target host hematopoietic stem cells (HSCs). A dose of 4  105 PCT STCs coinjected with 1 105 lineage-
depleted c-kit1 BALB/c HSCs resulted in 43.9% 6 3.3% CD41 and 10.9% 6 1.2% CD81 donor T cells in
blood, 29%6 7.8% and 21.7%6 4.0 donor B2201 IgM1 in spleen and bonemarrow, and 15.0%6 3.6% donor
Gran-11 cells in bone marrow at 6 months post-HSCT versus 0.02% 6 0.01%, 0.13% 6 0.10%, 0.53% 6
0.16%, 0.49% 6 0.09%, and 0.20% 6 0.06%, respectively, in controls who did not receive PCT STCs. We
found that STCs target host HSCs and that PCT STCs are detectable only up to 24 hours after infusion,
in contrast to non–photochemically treated STCs, which proliferate resulting in fatal GVHD. Increased mor-
tality in the groups receiving 4-6 105 PCT STCs was associated with evidence of GVHD, particularly in the
recipients of 6 105 cells. These results demonstrate that blocking NK cell–mediated resistance and making
niches in bone marrow are both essential to achieving multilineage engraftment of mismatched donor cells
and T cell and B cell reconstitution, even though GVHD is not completely eliminated.
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6/j.bbmt.2011.10.017function [1]. With the exception of gene therapy for
some types of SCID [2], allogeneic hematopoietic
stem cell transplantation (HSCT) is the only curative
treatment for children with SCID [3,4]. The
majority of affected children are unique in that they
can be treated successfully with an allogeneic graft
without previous conditioning with alkylating agents.
In contrast, HSCT to treat all other diseases
commonly requires alkylating agents to open up
marrow niches and prevent rejection mediated by
T cell immunity. However, some children with SCID
who undergo HSCT without any conditioning may
demonstrate incomplete T cell and often limited
B cell reconstitution [1,5-7]. For this reason, many
transplantation centers use high-dose alkylating
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[8]. In addition to the potential toxic effects of this
approach in infants and young children, some types
of SCID that result from defects in V(D)J recombina-
tion are associated with defects in DNA repair and
increased sensitivity to alkylating agents [3,5,9].
Approaches to opening marrow niches without the
need for alkylating agents would be especially useful
in treating these children, as well as possibly other
children with nonmalignant diseases in which full
100% donor chimerism is not essential.
There is a very high incidence of T2B2NK1
SCID in Athabascan-speaking Native American
children that is associated with a founder mutation in
Artemis (SCIDA), a key protein in the V(D)J recombi-
nation and nonhomologous DNA repair pathways
[10,11]. We previously reported our experience with
transplantation in a large number of Athabascan-
speaking Navajo children with this mutation [3]. Not
only do these children have a virtual absence of T
and B cells, but their fibroblasts demonstrate increased
sensitivity to ionizing radiation [12]. These children
also appear to have clinical manifestations of increased
sensitivity to alkylating agents and radiation [3].
Moreover, they typically reject haplocompatible T
cell–depleted grafts unless some kind of immunosup-
pressive conditioning therapy is used to prevent NK-
mediated graft rejection [13-15]. However, because
of their increased susceptibility to alkylating agents,
these children demonstrate increased morbidity and
mortality when exposed to this kind of conditioning.
Finally, when only immunosuppressive therapy is
used, these children typically reconstitute only T cell
immunity.
Previous studies have suggested that donor cell
engraftment by HSCT can be achieved without condi-
tioning therapy, provided that an adequate number of
marrow niches are available [16]. Therefore, optimal
conditions for successful HSCT in patients with
SCIDA require both overcoming NK-mediated resis-
tance and increasing the availability of niches. These
objectives must be achieved by means that do not
depend on alkylating agents or ionizing radiation. We
have developed a nonleakymousemodel of Artemis de-
ficiency that mimics the immunologic phenotype seen
in children with SCIDA [12,17]. We have previously
demonstrated that allogeneic-mismatched cytotoxic
donor T cells sensitized to host splenocytes and treated
with psoralen andUVA light (photochemical treatment
[PCT]) are capable of creating marrow space in recipi-
ent wild-type (WT) fetal mice [18]. The coinjection of
these cells with donor hematopoietic stem cells
(HSCs) in utero resulted in durable multilineage
engraftment with minimal GVHD [18]. In the present
study, we demonstrate that the combined administra-
tion of anti-NKantibody andPCT-sensitized cytotoxic
T cells (STCs) is a novel method for overcoming graftresistance and achieving multilineage engraftment in
young adult SCIDAmice.We also show that STCs tar-
get host HSCs and that with PCT, they maintain their
cytotoxic capability but have a relatively short life span
in vivo. In contrast, without PCT, SCTs are capable of
expanding in vivo and causing fatal GVHD. Extrapola-
tion of these methods to patients with SCIDA may en-
able the development of effective conditioning
regimens without alkylating agents or ionizing radia-
tion for successful HSCT.
MATERIALS AND METHODS
Mice
C57Bl/6 (B6, H-2b) and BALB/c (H-2d) WT mice
were purchased from Jackson Laboratory (Bar Harbor,
ME). The WT mice were mated to generate F1 haplo
mice (B6  BALB/c F1). Generation of the N10 B6
(99.9%) Artemis-deficient (mArt2/2) mice has been de-
scribed previously [12,17]. All animals were maintained
in the University California San Francisco Laboratory
Animal Resource Center’s Rodent Barrier Facility. All
animal procedures were approved by the university’s
Institutional Animal Care and Use Committee in
accordance with National Institutes of Health animal
care guidelines.
Anti-NK 1.1 Monoclonal Antibody and
Conditioning
The generation of the monoclonal antibody (mAb)
PK136, which recognizes NK1.1, has been described
previously [19]. This cell line was kindly provided
by Dr. William Seaman, Department of Medicine,
University of California San Francisco. The mAb
was produced as ascites in mArt2/2 mice and purified
by ammonium sulfate precipitation, and the total pro-
tein concentration was determined by UV absorption
at 280 nm. Five-week-old mArt2/2 mice were treated
weekly with 200 mg of anti-NK 1.1 mAb via i.p. injec-
tion for 3 weeks before transplantation with HSCs
and/or sensitized T cells.
Generation of Sensitized T Cells
To generate BALB/c donor T cells that were sen-
sitized to B6 mice, 3-month-old WT BALB/c mice
were injected i.p. weekly for 3 weeks with 10  106
splenocytes from WT B6 mice [18].
Isolation of Sensitized CD31 and CD8a1 T Cells
and NK Cells
CD31 or CD8a1 T cells from sensitized mice and
NK cells from unsensitized mice were enriched by
negative selection from spleens using microbeads and
the Midi-MACS System (Miltenyi Biotec, Auburn,
CA) following the manufacturer’s instructions.
The purity of CD31 T cells, CD8a1 T cells, and
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respectively, by flow cytometry.
Photochemically Treated STCs
Sensitized BALB/c CD31 or CD8a1 T cells were
pretreated with methoxsalen (Uvadex; Therakos,
Exton, PA) at 20 ng/mL in RPMI 1640 (5% fetal
bovine serum) medium or indicated concentrations
and exposed to UVA light for 2 minutes (PCT-2) or
4 minutes (PCT-4) (equivalent to 1 or 2 joules, respec-
tively) using a UVA irradiator (Cole-Parmer, Chicago,
IL) [18]. PCT-4 was used for most of the experiments.
Cells were then washed three times with RPMI 1640
(10% fetal bovine serum) medium and were injected
with or without donor HSC into recipient mice as
described in Results. Aliquots were evaluated for
proliferative response to anti-CD3, expression of
CD25 and CD69, and 51Cr release cytotoxicity.
51Cr Release Assay
51Cr release was measured to assess NK-mediated
cytotoxicity against Yac-1 tumor cells as described
previously [19]. Sensitized BALB/c CD31 or CD8a1
T cells were isolated from sensitized BALB/c mouse
spleens (mentioned previously) and used as effector
cells against 51Cr-labeled B6 splenocyte or lin2c-kit1
HSC targets in an overnight 51Cr-release assay
(RPMI 1640 medium, 10% fetal bovine serum, 1
Hepes buffer, 1 nonessential amino acid, 1 sodium
pyruvate, and 1 glutamine) and the University of
California San Francisco’s Cell Culture Facility [18].
HSCT
BALB/c WT mice (2-4 months old) were used as
donors for mArt2/2 B6 (CD45.2) recipients. The do-
nor bone marrow lin2 c-kit1 HSC preparations were
generated using the Lineage Cell Depletion Kit and
CD117 (MicroBeads (Miltenyi Biotec) per the manu-
facturer’s instructions (Miltenyi Biotec), and .95%
c-kit1 (CD1171) was verified by flow cytometry. A to-
tal of 1 105 lin2c-kit1 allogeneicmismatched BALB/
c HSCs with or without STCs (6PCT) were injected
via the tail vein into recipient mArt2/2 B6 mice at 8
weeks of age. The mArt2/2 B6 mice had received pre-
vious anti-NK1.1 mAb injections as indicated. After
transplantation, the mice were maintained in the Lab-
oratory Animal Resource Center’s barrier facility with
antibiotic-supplemented water. Controls included
age-matched B6mArt2/2mice, B6WTmice, and het-
erozygotes that received a sham injection or HSCs.
Assessment of GVHD
The severity of GVHD was assessed based on the
percent weight change [20,21]. Weights were recorded
on day 1l and weekly until euthanasia occurred.
GVHD was scored using a system incorporating fiveclinical parameters: weight loss, posture (hunching),
activity, fur texture, and skin integrity. Mice were
given a score of 0-2 for each parameter. A clinical
index was generated by summing the five scores [22].
Secondary HSCT
Lin2c-kit1 bone marrow HSCs were isolated at
3-6 months post-HSCT from mArt2/2B6 mice that
underwent previous transplantation with allogeneic
BALB/c HSCs. A total of 1  105 HSCs were injected
via the tail vein into lethally irradiated (9 Gy) B6 
BALB/c F1 mice (10-12 weeks old) using a 137cesium
animal irradiator (model 520A; Xetex, Sunnyvale,
CA) [16].
Multilineage and Chimerism Analyses
T cell, B cell, and granulocyte phenotyping and
chimerism were analyzed in blood obtained from the
lateral saphenous vein (at 4-week intervals) and single
cell suspensions (at .5 months) of spleen, thymus,
lymph node, and bone marrow by flow cytometry
using a four-color FACSCalibur, and the resulting
data were processed using Cell Quest Pro software
(BD Biosciences, San Jose, CA). Fluorescently conju-
gated antibodies (BD Pharmingen, San Diego, CA or
e-Bioscience, San Diego, CA) to BALB/c (anti–H-2d)
donor, B6 (anti–H-2b) recipient, CD45, CD3, CD4,
CD8, CD45r/B220, CD25, CD69, and Ly6G/C
(Gran-1) were used. In addition, anti-CD45r/B220
and anti-IgM antibodies were used to examine B cell
maturation in bone marrow and peripheral blood.
Proliferation Assays
In proliferation assays, 4  105 post-Ficoll spleno-
cytes were stimulated with either lipopolysaccharide or
anti-CD3 as described previously [17].
T Cell Receptor Vb Quantitative Immunoscopy
RNA was obtained from T cells isolated from
thymus or spleen using a pan–T cell negative selection
kit (Miltenyi Biotec). T cell receptor (TCR) Vb reper-
toire analysis was modified and performed as described
previously [17].
Enzyme-Linked Immunosorbent Assay for
Serum IgM and IgG Antibodies
Tomeasure antibody responses,micewere injected
i.p. with 100 mg of 4-hydroxy-3-nitrophenylacetyl hap-
ten 24-keyhole limpet hemocyanin (NP24-KLH;
Biosearch Technologies, Novato, CA) and boosted
with an additional 100 mg of NP24-KLH at 5 weeks
after the initial injection. Postimmune serum was col-
lected at 1 week after theNP24-KLHboost via a blood
draw from the saphenous vein and stored at 220C.
NP24-KLH–specific antibody response was measured
by sandwich enzyme-linked immunosorbent assay [17].
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Carboxyfluorescein succinimidyl ester (CFSE) is
an intracellular fluorescent dye that is retained in
daughter cells during cell division. Here, 6  105
STCs or PCT-4 STCs were washed twice in
phosphate-buffered saline (PBS) and labeled with
10-mM CFSE binding dye (Invitrogen, Carlsbad,
CA), incubated at 37C for 10 minutes, cooled on
wet ice, and resuspended in culture medium, then in-
jected i.v. into B6 mArt2/2B6 mice and assayed for
proliferating cells after 2, 24, 48, and 72 hours.
Phycoerythrin-conjugated anti-CD3 monoclonal an-
tibody (BD Pharmingen) was used to identify the T
cell population, and CFSE intensity was analyzed
with a FACSCalibur flow cytometer (BD Biosciences).
A population of T cells that had proliferated exten-
sively in different tissues was identified based on
CFSE dye dilution [23,24].Competitive Repopulation Experiment
To assess the marrow cell targets of STCs, 10- to
12-week-old (B6 BALB/c) F1 recipients were irradi-
ated with a single fraction of 9 Gy using a 137cesium
animal irradiator (520A; Xetex), which was uniformly
sublethal in the absence of donor cells. Competitive
repopulation experiments were performed by coinject-
ing into the dorsal tail vein of the irradiated recipients
equal numbers of unmanupulated mArt2/2 B6 HSCs
or mArt2/2 B6 HSCs from animals that had been
injected with 4  105 BALB/c PCT-4 STCs 24 hours
earlier, combined with na€ıve WT BALB/c bone mar-
row cells [25]. At 2 and 4 months post-HSCT, periph-
eral blood was obtained from the lateral saphenous
vein of the recipients and stained using fluorescently
conjugated antibodies to BALB/c (anti–H-2d) and B6
(anti–H-2b) [16].Histology
The tissues (liver, gut, and skin) removed from
euthanized animals were placed into cold PBS to
remove all blood and then were placed into 70% etha-
nol fixative and kept overnight at 4C. All tissues were
processed following the standard hematoxylin and eo-
sin staining protocol at the University of California
San Francisco’s immunohistochemistry facility.Statistical Analysis
The independent-samples t-test or the nonpara-
metric unpaired Mann-Whitney test was used to test
goodness of fit and independence. In the Kaplan-
Meier survival analysis, the overall comparison used
either the log-rank or generalized Wilcoxon test to
determine differences between the various PCT-4
STC doses.RESULTS
Long-Term, Multilineage Engraftment after
Anti-NK1.1 mAb Treatment and Coinjection of
PCT-4 STCs with Allogeneic HSCT
We found that administration of anti-NK1.1 mAb
suppressed NK cytotoxic function to an extent compa-
rable to that reported previously (Figure S1A) [19,26].
We also found that PCT inhibited proliferation of
STCs while maintaining the cytotoxic activity and
expression levels of activation markers CD25 and
CD69 and that the optimal UVA dose was PCT-4,
equivalent to 2 joules (Figure S1B-D). To investigate
whether administration of pretransplantation anti-
NK1.1 mAb and coinjection of PCT STCs might be
required for effective allogeneic HSCT and to address
whether PCT STCs promote multilineage engraft-
ment in a dose-dependent manner, we transplanted
1  105 lin2c-kit1 BALB/c HSCs in combination
with various concentrations (1, 2, 4, and 6  105) of
BALB/c PCT-4 STCs into 8-week-old B6 mArt2/2
mice pretreated with anti-NK1.1 mAb. At 2 months
post-HSCT, neither anti-NK antibody nor PCT-4
STCs alone resulted in significant donor engraftment,
with the optimal engraftment of donor T and B cells
seen in anti-NK–treated mice that received 4  105
PCT-4 STCs plus HSCs (Figure S2A). In addition,
multilineage engraftment at 2 months was optimized
at that cell dose (Figure S2B).
Long-term (6 months) evidence of recovery of
both T cell and B cell numbers and function was
seen only in the group treated with 4  105 PTC-4
STCs (Figure 1). Normal numbers of splenic lym-
phocytes were observed (Figure 1A) in all long-
term surviving mice (n 5 7) in this group. These
mice achieved normal to near-normal numbers of
mature CD41 cells (43.9% 6 3.3%, 21.1% 6
2.6%, 39.6% 6 2.1%, and 8.3% 6 0.1%) and
CD81 cells (10.9% 6 1.2%, 6.0% 6 1.0%, 13.7%
6 0.8%, and 2.1% 6 0.1%) in peripheral blood,
spleen, lymph node, and thymus, respectively
(Figure 1C and D). Likewise, phenotype analysis us-
ing antibodies to B220 and IgM cell surface markers
revealed the presence of mature B cells at significant
levels in spleen (29.0% 6 7.8%) and bone marrow
(21.7% 6 4.0%) (Figure 1B). The results of flow cy-
tometry analysis are shown in Figure S3A. Consistent
with peripheral blood granulocyte chimerism at 8
weeks post-HSCT (Figure S2B), granulocyte engraft-
ment in bone marrow (Figure 1E) was also achieved
in long-term survivors that received 4  105 PCT-4
STCs plus 1  105 HSCs (15% 6 3.6%) compared
with recipients of 1  105 (0.2% 6 0.1%; P\ .01),
2  105 (1.5% 6 1.2%; P \ .05), and 6  105
(0.7% 6 0.3%; P\ .01) PCT-4 STCs and 1  105
HSCs.
Figure 1. Effects of anti-NK mAb 1.1 and various doses of PCT-4STC on lymphoid and myeloid long-term reconstitution after allogeneic HSCT. (A)
Total number of lymphocytes in the spleen of recipient mice 6 months after HSCT compared with unmanipulated WT B6 (positive control) and B6
mArt2/2 (negative control) mice. Values are mean 6 standard error of the mean (SEM) (n 5 3-7). **P\.01. (B) Donor mature B cells (B2201IgM1)
in spleen and bone marrow (BM). (C) CD41, (D) CD81 mature T cell phenotyping in peripheral blood (PB), spleen, lymph node (LN), and thymus
from WT B6 mice (n 5 3), B6 mArt2/2 untransplanted mice (n 5 6), and B6 mArt2/2 mice after allogeneic HSCTwith anti-NK 1.1 mAb and PCT-
4STC (4 105) (n5 7) at$6 months post-HSCT. Mean values6 SEM are shown. (E) Donor granulocyte chimerism in BM from B6mArt2/2mice after
allogeneic HSCTwith anti-NK 1.1 mAb and various doses of PCT-4 STCs (1-6  105). Values are mean 6 SEM (n 5 3-7). **P\.01; *P\.05.
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and lipopolysaccharides were also tested after
HSCT. Splenocytes from surviving mice that received
4 or 6  105 PCT-4 STCs had significantly improved
in vitro proliferative responses to T and B cell
mitogens compared with B6 mArt2/2 mice (P\ .01)
(Figure 2A). Splenocytes from surviving mice that
received 1 or 2  105 PCT-4 STCs did not show
improved in vitro proliferative responses compared
with those from control B6 mArt2/2 mice (P . .05).
Although some recipients of 2  105 PCT-4 STCs
did demonstrate positive proliferative responses to
mitogens, these responses were highly variable.
To evaluate B lymphocyte function after HSCT,
we immunized recipient mice with the T cell–
dependent antigen NP24-KLH. IgM responses wererelatively lower in the 4 105 PCT-4 STCmice com-
pared with B6 WT mice (Figure 2B), whereas no sig-
nificant difference in IgG antibodies was seen
between these two groups of mice (Figure 2C). Spe-
cific but relatively lower levels of IgM (Figure 2B)
and IgG (Figure 2C) antibodies to NP24-KLH were
detected in the recipients of 6  105 PCT-4 STCs.
To assessT cell diversity in themice that underwent
transplantation, we investigated the TCRVb repertoire
in T cells. In the mice undergoing allogeneic HSCT
with 2 105 or 4 105 PCT-4 STCs, near-normal pat-
terns were observed in all four of the regions analyzed
compared with the normal Gaussian distribution of the
different CDR3 lengths in WT mice (Figure 2D). In
the 6  105 PCT-4 STC group, the T cell repertoire
had skewed profiles or monoclonal patterns in the
Figure 2. Tand B cell proliferative responses, specific IgM and IgG re-
sponses postimmunization, and T cell receptor diversity post-HSCT. (A)
Proliferative responses of lymphocytes to anti-CD3 and lipopolysaccha-
rides. WT B6 mice were compared with B6 mArt2/2 untransplanted
mice (negative controls), recipients of allogeneic HSCT with anti-
NK1.1 mAb and various doses of PCT-4 STC $6 months post-HSCT.
Results (stimulated minus resting) are expressed as counts per minute
(cpm) on a log scale (n . 3). **P\ .01. (B and C) Serum IgM-specific
(B) and IgG-specific (C) antibody response to NP24-KLH after immuni-
zation (minus preimmune response). Average response from recipients
(n . 3) of allogeneic HSCTwith anti-NK 1.1 mAb and various doses of
PCT-4 STCs are compared with B6 mArt1/1 (n 5 3) and B6 mArt2/2
(n 5 3) controls with serial dilutions. (D) TCRVb repertoire analysis.
Four representative Vb regions are shown. T cells were enriched
from either thymus or spleen and prepared as described in Materials
and Methods. ‘‘Leaky’’ refers to a representative 129/SvJmArt2/2mouse
[17]. Examples of the repertoire from mArt2/2 recipients of allogeneic
HSCT (851, 829, and 627 are serial numbers) with 2, 4, and 6  105
PCT-4 STCs are shown as well.
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stricted clonal expansion of the engrafted T cells. The
comparative TCRVb repertoire analysis for the 1 
105 PCT-4 STC group was not possible because of an
absence of T cells or a limited number of T cells.
To investigate whether donor repopulating stem
cells had engrafted in recipient mice, we performed
two secondary transplant experiments (n5 3 recipients
per experiment). Both experiments resulted in multili-
neage BALB/c donor engraftment (Figure S3B).PCT Limited, but Did Not Completely
Abrogate, GVHD
To assess the severity of GVHD, the percent
weight change after HSCT was recorded. Weight
loss of .10% was considered indicative of significant
GVHD [14-16]. None of the recipients of up to
4 105 PCT-4 STCs lost.10% of their initial weight
even at 1 week post-HSCT. Evaluation of control mice
that received 1  105 allogeneic donor HSCs plus
6  105 STCs not treated with PCT (6  105 non-
PCT in Figure 3A) revealed that nearly 100% had
a weight loss of .10% (most .30%), a threshold
described for clinically important GVHD at 5 weeks
post-HSCT (Figure 3A). The percentage of weight
change at 5 weeks in this control group (228.8% 6
0.9%) was significant (P\ .05) only when compared
with mice that received 1  105 allogeneic donor
HSCs plus 1  105 (2.6% 6 0.8%), 2  105
(22% 6 0.2%), 4  105 (21% 6 0.2%), or 6  105
(28.8%6 0.3%) PCT-4 STCs (Figure 3A). However,
the weight changes at 1, 2, 4, and 5 weeks post-HSCT
in the 6 105 recipient group do appear to differ from
those in the other experimental groups and possibly
could be consistent with GVHD. We used a clinical
scoring system to further assess GVHD (see Materials
and Methods for details). Nearly 100% of the mice
receiving 6  105 non-PCT-4 STCs failed to gain
weight, lost fur, and displayed abnormal posture and
limited activity, all signs of GVHD [14-16]. As
shown in Figure 3B, this semiquantitative assessment
demonstrated that clinical scores did not differ signif-
icantly between mice receiving 6  105 PCT-4 STCs
and non–PCT-4 control mice (7.2 6 0.9 versus
9.36 0.5). However, there were significant differences
in GVHD scores between allogeneic HSCT recipient
mice in the non–PCT-4 STC control group and
recipient mice treated with 1  105 PCT-4 STCs
(1.4 6 0.2), 2  105 PCT-4 STCs (1.4 6 0.4), and
4  105 PCT-4 STCs (3.1 6 0.9) (P\ .05). There
was also a significant difference in GVHD scores of
allogeneic HSCT recipient mice treated with 4  105
PCT-4 STCs and those treated with 6  105 PCT-4
STCs (P \ .05) but no significant difference
between the 1 105 and 4 105 PCT-4 STC recipient
groups (P . .05). Histological analysis of mice that
Figure 3. PCT-4 of sensitized donor T cells limits GVHD and prolongs
survival. (A) Percentage of weight change in mice after allogeneic HSCT.
Themicewereweighed individually on day11 and thenweekly up to the
day of analysis. At 5 weeks after allogeneic HSCT, the percentage of
weight loss was significant only in the group treated with 6  105
non–PCT-4 STCs. Values are expressed as mean 6 SEM (n 5 4-10
per group, *P\.05). (B) Clinical GVHD scores of mice at 5 weeks after
allogeneic HSCT. These mice were evaluated for evidence of clinical
GVHD as described in Materials and Methods. Scores are expressed
as mean 6 SEM (n 5 4-10 per group; *P\.05). (C) Kaplan-Meier sur-
vival 180 days after HSCT with 1  105 HSCs plus varying doses of
PCT-4 STCs. Control mice received 1  105 HSCs plus 6  105
STCs. Analysis by independent samples t-test of mean survival (days)
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(6PCT) further supported the finding that PCT sig-
nificantly limits GVHD in all recipients of PCT-4
STCs, although to a lesser extent in recipients of the
6  105 dose (Figure S4).Survival of Mice Treated with PCT-4 STCs and
Allogeneic Mismatched Donor HSCs
Without PCT-4 STCs, all four mice treated with
6  105 STCs died within 6 weeks (Figure 3C).
With PCT-4 STCs, long-term (180 days) estimated
survival rates and mean survival times were 100% 6
0% and 180 6 0 days for mice receiving 1  105
PCT-4 STCs (n 5 5), 80% 6 18% and 171 6 8 for
mice receiving 2  105 PCT-4 STCs (n 5 5), 60% 6
15% and 129 6 20 for mice receiving 4  105 PCT-4
STCs (n5 10), and 50%6 16% and 1316 18 days for
mice receiving 6  105 PCT-4 STCs (n 5 10).PCT-4 STCs are Capable of Making Niches in
Bone Marrow
To determine whether PCT-4 STCs actually
target repopulating stem cells, sensitized BALB/c
CD8a1T cells were generated and assayed in an over-
night culture with 51Cr- labeled B6 WT lin2c-kit1
HSCs. At a 50:1 effector-to-target ratio, 70% 6
15.1% cytotoxicity was seen with STC alone, and
63% 6 12% was seen when PCT-4 STCs were used.
Comparable levels of 51Cr release in the two T cell
populations were achieved at other effector-to-target
ratios as well (Figure 4A).
To further confirm depletion of functional HSCs,
we infused PCT-4 STCs into anti-NK1.1 mAb-
treated B6 mArt2/2 mice, then 24 hours later, co-
transplanted treated 1  105 lin2c-kit1HSCs isolated
from the bone marrow of these mice with an equal
number of HSCs from BALB/c WT mice into le-
thally irradiated B6  BALB/c F1 recipients. Evalua-
tion of engraftment in the F1 recipient mice at 2
months post-HSCT revealed 0.4% 6 0.1% B6 versus
55.7% 6 6.8% BALB/c granulocyte engraftment in
these F1 recipients compared with 11.3% 6 2.6%
B6 versus 64.7% 6 9.9% BALB/c granulocyte en-
graftment in F1 recipients of equal numbers of
HSCs from bone marrow of untreated B6 mArt2/2
and BALB/c WT mice (Figure 4B). This represents
a significant difference in B6 granulocyte chimerism
(P \ .05) and reflects an 30-fold decrease in the
number of transplanted functional donor HSCs inwere significant only for recipients of 1 versus 4  105 PCT-4 STC
(P 5 .04) and 1 versus 6  105 PCT-4 STC (P 5 .03). There was no sig-
nificant difference in the overall comparison of survival curves between
recipients of 1, 2, 4, and 6  105 PCT-4 STC (P 5 .50) using log-rank or
generalized Wilcoxon analysis.
Figure 4. PCT STCs create niches in recipient bone marrow, and PCT-
4 decreases survival of STCs. (A) Cytotoxicity of sensitized CD8a1 T
cells (BALB/c) with or without PCT-4. Killing of B6 lin2c-kit1 HSCs
was assessed in an overnight chromium-release assay. The control was
nonsensitized T cells. Each dot represents the mean 6 SEM for killing
by T cells (n 5 3) using ratios of 12:1, 25:1, and 50:1, respectively. (B)
Competitive repopulation experiments with equal amounts of un-
treated BALB/c and B6 lin2c-kit1HSCswith or without preconditioning
with donor PCT-4 STCs. The bar graph shows the percentages of en-
grafted granulocytes for BALB/c and C57B1/6 (B6) in B6  BALB/c F1
recipients at 2 months post-HSCT (n 5 3). *P \ .05. See Materials
and Methods for details. (C) Survival kinetics of STCs in vivo. Purified
STCs (donor, BALB/c) with or without PCT-4 were labeled with CFSE
and administered i.v. to B6 mArt2/2 mice preconditioned with anti-
NK1.1 mAb. Bone marrow was harvested and evaluated for CFSE-
positive cells at various time points. Shown is a representative result
from three independent experiments. See Materials and Methods for
more details.
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in BALB/c granulocyte chimerism between the two
groups (P . .05).Persistence of PCT-4 STCs in NK-Depleted
mArt2/2 Mice
Although engraftment increased with increasing
numbers of PCT-4 STCs coinjected with a fixed num-
ber of HSCs, so did mortality. We first asked whether
PCT-4 STCs could survive in vivo. We infused
6 105 STCs with or without PCT-4 that had been la-
beled with CFSE into anti-NK1.1 mAb-treated B6
mArt2/2mice and tested for the presence of these cells
in different tissues over time. We found PCT-4 STCs
in the bone marrow at 2 hours postinjection but not at
24 and 48 hours postinjection (Figure 4C). In contrast,
STCs alone were still detectable at 48 hours after
injection and actually appeared to be increasing in num-
ber (Figure 4C). Similar results were obtained in the
blood and spleen (data not shown). We next investi-
gated whether the 4% to 5% of STCs that were still
capable of proliferating after PCT-4 of 6  105 STCs
could cause GVHD. We injected 25,000 STCs (4%
of 6 105, the number thatwe estimatewould have sur-
vived PCT-4 based on the proliferation assay) into anti-
NK1.1 mAb-treated B6 mArt2/2 mice (n 5 4). No
significant engraftment was found (data not shown),
and none of the four injected mice died, suggesting
that the small number of proliferating STCs remaining
after PCT-4 cannot explain the multilineage engraft-
ment seen with PCT-4 and cannot cause GVHD.DISCUSSION
We previously demonstrated that the C57Bl/
6 mArt2/2 mouse model accurately reflects SCIDA
in humans in that it is T cell and B cell deficient, is non-
leaky, has normal NK cell numbers and function, and
is sensitive to ionizing radiation [17]. This model also
is compatible with Artemis-deficient children, in that
the T cell defect, but not the B cell defect, can be cor-
rected by congenic HSCT, whereas allogeneic mis-
matched grafts (using BALB/c donors) are rejected
when conditioning therapy is not used [17].
In the present study, we found that coinjection
of allogeneic mismatched HSCs with donor T cells
sensitized to recipient antigens and treated with
psoralen and UVA light to prevent proliferation
achieved significant multilineage engraftment, with
full T and B cell reconstitution. Furthermore, in
secondary transplantations, lethally irradiated WT
recipients could be reconstituted with marrow from
primary engrafted mice. We confirmed that the
multilineage engraftment was due to engraftment of
donor HSCs.
We found that when PCT-4 STCs or anti-NK1.1
mAb were used independent of each other, only lim-
ited engraftment of allogeneic mismatched HSCs
occurred. The lack of efficacy of anti-NK1.1 mAb
alone may be explained by the existence of sufficient
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engraft, even when NK-mediated graft resistance is
reduced. Insufficient suppression of graft resistance is
also possible, given that only 60% of NK function
was eliminated by anti-NK1.1 mAb treatment alone.
Interestingly, injecting higher doses of anti-NK1.1
mAb into control animals resulted in significant
mortality but only modest additional reductions in
cytotoxic function (data not shown). We speculate
that PCT-4 STCs exert some antirecipient NK cell
activity, and the combination of these cells and anti-
NK1.1 mAb produces sufficient suppression of graft
resistance to allow robust engraftment.
Our in vitro experiments showed that the PCT-4–
sensitized BALB/c CD8a1 T cells directly target B6
HSCs. However, CD8a1 PCT-4 STCs in vivo had
no effect on engraftment (data not shown), similar to
what we previously found in an in utero transplant
model usingWTmice [18].We also performed a com-
petitive repopulation experiment to confirm that the
coinjection of donor PCT-4 STCs with HSCs would
target niches in the recipient marrow. Of note, injec-
tion of B6 mArt2/2 bone marrow that had been
exposed in vivo to PCT-4 STCs 24 hours earlier into
irradiated F1 recipients resulted in significantly
reduced B6HSC engraftment comparedwith injection
of B6 mArt2/2 bone marrow not exposed to PCT-4
STCs. The difference suggests that PCT-4 STCs can
target host HSCs and create niches in bone marrow.
Our evaluation of varying doses of PCT-4 STCs
found that 4  105 cells was the optimal dose for T
cell, B cell, and granulocyte engraftment. Minimal
engraftment occurred at the lowest dose (1 105 cells),
possibly due to insufficient generation of niches in
recipient bone marrow. Interestingly, at the highest
dose (6  105 cells), there was significantly reduced
T cell and B cell reconstitution in addition to the low-
est survival. This reduced engraftment and survival at
the highest dose used most likely is related to
GVHD, as indicated by elevated clinical GVHD
scores and greater histological liver damage. We
believe that GVHD damages the bone marrow niche
early, including stroma and osteoblasts, resulting in
poor engraftment [27].
Although the 4  105 dose pf PCT-4 STCs
resulted in the highest level of durable multilineage
engraftment and T cell and B cell immune reconstitu-
tion, only 70% of the animals that received this dose
survived for .180 days, with 30% dying at a mean of
52.5 6 4.9 days posttransplantation. In contrast to
what was seen in the 6  105 non-PCT control
animals, we found no consistent pathological evidence
of acute or chronic GVHD in these animals. In addi-
tion to inflammation and duct damage, cholestasis is
also common in patients with acute GVHD, but it
was not seen in this treatment group (or any other
group). Furthermore, the pathology results in the4  105 PCT-4 STC group indicated chronic inflam-
mation in the liver, raising the possibility that chronic
infection and/or hepatitis of unclear etiology might
have accounted for the 30% mortality. However, we
do not know whether T regulatory cells were elimi-
nated by PCT, which could lead to GVHD. It is also
possible that the PCT-4 STCs were not rendered
completely incapable of causing GVHD. Photochem-
ical treatment of donor STCs resulted in a significant
reduction in lymphocyte proliferation in vitro (while
maintaining cytotoxic capability and expression of
activation markers); however, there was a degree of re-
sidual proliferation, although nomore than 4%of con-
trol. We were concerned that these remaining cells
possibly could have resulted in GVHD. However, in-
jection of an equivalent number (2.5  104) of STCs
(without PCT-4) into anti-NK1.1 mAb pretreated
Artemis-deficient recipients resulted in no engraft-
ment, immune reconstitution, or mortality. After in-
jection of 6  105 CFSE-labeled PCT-4 STCs into
anti-NK1.1 mAb pretreated animals, these cells were
undetectable in the circulation or in various organs at
24 hours posttransplantation. In contrast, 6  105
STCs (without PCT-4) increased in number over
time after transplantation and resulted in 100% mor-
tality from GVHD.
Compared with other approaches [28,29], our
data demonstrate that major barriers to achieving
efficient allogeneic donor engraftment in mArt2/2
mice include recipient NK-mediated resistance and
occupancy of host bone marrow niches.We have dem-
onstrated that reduced NK cell function combined
with injection of PCT-4 STCs results in durable mul-
tilineage engraftment of major histocompatibility
complex–mismatchedHSCs and restoration of normal
T and B cell immunity in Artemis-deficient mice. Not
surprisingly, the PCT-4 STC dose is critical to this
response. Too low a dose will result in minimal en-
graftment, whereas too high a dose will result in
GVHD and poor reconstitution. In this study, the
optimal dose in terms of producing significant chime-
rism and full immune reconstitution was nonetheless
associated with some mortality of unclear etiology.
Our findings suggest that the challenge when applying
this treatment strategy will be to find a balance
between beneficial and harmful T cell effects.ACKNOWLEDGMENTS
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